Jan 15, 2020 / 06:30PM GMT
Jessica Macomber Fye - JP Morgan Chase & Co, Research Division - Analyst
Hey, good morning, everyone. My name is Jess Fye. I'm one of the biotech analysts at JPMorgan, and we're continuing the 2020 Healthcare Conference this morning with Amarin. We're going to host a Q&A session with the management team right after this. It's just across the hall in the Georgian room. But for the presentation, I'm going to turn it over to the company's CEO, John Thero.
John F. Thero - Amarin Corporation plc - President, CEO & Director
Thank you, Jess, for the introduction. Thank you, everybody, for joining me here today. At this -- in the same room, last year around this time, was presenting to, broad acclaim, both the significant revenue growth we had in the prior year, but also the results of our landmark cardiovascular outcome study for our lead drug, Vascepa. This year, I'm presenting following even further growth in our revenues, but also after the first ever FDA approval of a drug for cardiovascular risk indication that's important, and we'll be talking about.
Amarin Corporation PLC at 38th Annual J.P Morgan Healthcare Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers